Australia’s most successful manufacturer, biotechnology company CSL today reported net profit after tax of $2.64 billion for the 12 months ended 30 June 2024, up 25 percent on a constant currency basis. Net profit after tax (NPATA) was $2.91 billion, up 15 percent on revenue up 11 percent to $14.8 billion. CSL’s Chief Executive Officer…
Biotechnology giant CSL has reported net profit after tax for the six months ended December 31 of $1.9 billion, up 20 percent on the previous corresponding period. Underlying net profit was $2.02, set on revenue up 11 percent to $8.05 billion. CSL CEO and Managing Director Dr Paul McKenzie said: “Our strong first half result…
Melbourne biotechnology giant CSL has hit back at doubters posting a massive rise in revenues for the year. The company, which has been questioned by analysts about its recent acquisition of the Vifor pharmaceutical business, reported revenues up 31 percent at constant currency value to $13.31 billion for FY23. Sales for CSL Vifor in the…